Home » Market News » DirectorsTalk Highlights » Venn Life Sciences non-clinical development
Open Orphan PLC

Venn Life Sciences non-clinical development

Non-clinical testing is conducted throughout all phases of drug development to assess the safety profile and pharmacokinetic and toxicokinetic (PK/TK) characteristics of candidate medicinal products. Optimised non-clinical (or preclinical) development can maximize the chances of success in clinical development.

Strategies for the non-clinical development of products follow general regulatory guidelines and can also be developed on a case-by-case basis depending on the specifics of the drug. It is of key importance to design an optimal preclinical development program that enables the drug candidate to be progressed into the clinic (“e.g. IND package”), or a more extended non-clinical development plan enabling the drug to be taken to the next clinical phase, or to product registration. The project managers at Venn can guide the client though all these phases of drug development.

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data). 

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.